Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Vieito

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
BMJ Case Reports|April 9, 2020
Grade I meningioma with disseminated bone disease: a rare clinical phenomenonOriol Mirallas, David Marmolejo, Augusto Valdivia, et al.
Medical Sciences (Basel, Switzerland)|July 25, 2023
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated TumorsCristina Suárez, Maria Vieito, Augusto Valdivia, et al.
Cancer Treatment Reviews|May 19, 2024
Agnostic drug development revisitedAlberto Hernando-Calvo, Alice Rossi, Maria Vieito, et al.
Cancer Research Communications|August 30, 2023
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing RegimensJosep Tabernero, Philippe L Bedard, Yung-Jue Bang, et al.
Cancers|January 24, 2014
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic TreatmentLaura Muinelo-Romay, Maria Vieito, Alicia Abalo, et al.
The Oncologist|October 16, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 resultsIben Spanggaard, Marc Matrana, Caio Rocha Lima, et al.
Nature Medicine|July 31, 2025
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trialScott Kopetz, Valentina Boni, Ken Kato, et al.
Medical Image Analysis|March 12, 2025
SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancerAnna Kira Voronova, Athanasios Grigoriou, Kinga Bernatowicz, et al.
Scientific Reports|December 1, 2016
Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung CancerJavier Mariscal, Marta Alonso-Nocelo, Laura Muinelo-Romay, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 9, 2026
Inequities in enrollment across clinical trial phases and the need for a Spanish perspectiveJavier Torres-Jiménez, Javier David Benítez Fuentes, Mónica Guillot Morales, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
BMJ Case Reports|April 9, 2020
Grade I meningioma with disseminated bone disease: a rare clinical phenomenonOriol Mirallas, David Marmolejo, Augusto Valdivia, et al.
Medical Sciences (Basel, Switzerland)|July 25, 2023
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated TumorsCristina Suárez, Maria Vieito, Augusto Valdivia, et al.
Cancer Treatment Reviews|May 19, 2024
Agnostic drug development revisitedAlberto Hernando-Calvo, Alice Rossi, Maria Vieito, et al.
Cancer Research Communications|August 30, 2023
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing RegimensJosep Tabernero, Philippe L Bedard, Yung-Jue Bang, et al.
Cancers|January 24, 2014
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic TreatmentLaura Muinelo-Romay, Maria Vieito, Alicia Abalo, et al.
The Oncologist|October 16, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 resultsIben Spanggaard, Marc Matrana, Caio Rocha Lima, et al.
Nature Medicine|July 31, 2025
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trialScott Kopetz, Valentina Boni, Ken Kato, et al.
Medical Image Analysis|March 12, 2025
SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancerAnna Kira Voronova, Athanasios Grigoriou, Kinga Bernatowicz, et al.
Scientific Reports|December 1, 2016
Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung CancerJavier Mariscal, Marta Alonso-Nocelo, Laura Muinelo-Romay, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 9, 2026
Inequities in enrollment across clinical trial phases and the need for a Spanish perspectiveJavier Torres-Jiménez, Javier David Benítez Fuentes, Mónica Guillot Morales, et al.
Pageof 4